MET and non-small cell lung carcinoma: Although MET TKIs, such as tepotinib and capmatinib, are more selective and potent agents than crizotinib (an ALK-TKI), it was also found to be safe and effective in MET inhibition in patients with advanced METex14-altered NSCLC in PROFILE 1001 trial [58].